In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma
Advances in therapies targeting proteins and pathways affected by genetic alterations has raised the possibility of personalized cancer treatments. The efficacy of targeting molecular aberrations was determined in the pancreatic ductal adenocarcinoma (PDAC) cell line, CAPAN2. Two mutations were targ...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2018-04, Vol.38 (4), p.1967-1977 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1977 |
|---|---|
| container_issue | 4 |
| container_start_page | 1967 |
| container_title | Anticancer research |
| container_volume | 38 |
| creator | Bush, Kevin T Boichard, Amelie Tsigelny, Igor F |
| description | Advances in therapies targeting proteins and pathways affected by genetic alterations has raised the possibility of personalized cancer treatments.
The efficacy of targeting molecular aberrations was determined in the pancreatic ductal adenocarcinoma (PDAC) cell line, CAPAN2. Two mutations were targeted, KRAS (p.G12V) and ABL1 (p.G1060D), and cells were treated with regorafenib and trametinib, individually and in combination.
Exposure to either drug significantly increased cell death compared to the current standard of care, gemcitabine. Treatment with combinations of the drugs led to significant increases in cell death compared to either monotherapy. Strong additive/synergistic interactions were observed across a range of dosages and ratios, reducing dose requirements with potential clinical relevance.
The data obtained in this PDAC cell model: i) support the use of matched monotherapies; ii) indicate the effectiveness of matched combination therapies; and iii) provide potential proof-of-concept for precision medicine approach to cancer treatment. |
| doi_str_mv | 10.21873/anticanres.12434 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2020494453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2138071294</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-dcd22de72496593e1366b68af57e3182a1d01defef49d6832f2c93eed61116a93</originalsourceid><addsrcrecordid>eNpdkMtKxTAQhoMoerw8gBsJuHFTzSRp2izlHG8gKHjZlpxkKpE20aRdnLe3eryAq2GG7_8ZPkIOgZ1yqCtxZsLgrQkJ8ylwKeQGmUGloahKwTbJjPGSFRVj5Q7ZzfmVMaV0LbbJDtel1gL4jJibQJ_9kCK96EbrnRl8DDS2dJHGFzqP_dKH9e1hFTC9rKgP9DGhGXoMwyd4b4L93L2li9EOpqPnDkO0JlkfYm_2yVZruowH33OPPF1ePM6vi9u7q5v5-W1hBZdD4azj3GHFpValFghCqaWqTVtWKKDmBhwDhy22UjtVC95yO2HoFAAoo8UeOVn3vqX4PmIemt5ni11nAsYxN5xxJrWUpZjQ43_oaxxTmL5rOIiaVcC1nChYUzbFnBO2zVvyvUmrBljz5b_58998-Z8yR9_N47JH95v4ES4-AHoJg2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138071294</pqid></control><display><type>article</type><title>In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bush, Kevin T ; Boichard, Amelie ; Tsigelny, Igor F</creator><creatorcontrib>Bush, Kevin T ; Boichard, Amelie ; Tsigelny, Igor F</creatorcontrib><description>Advances in therapies targeting proteins and pathways affected by genetic alterations has raised the possibility of personalized cancer treatments.
The efficacy of targeting molecular aberrations was determined in the pancreatic ductal adenocarcinoma (PDAC) cell line, CAPAN2. Two mutations were targeted, KRAS (p.G12V) and ABL1 (p.G1060D), and cells were treated with regorafenib and trametinib, individually and in combination.
Exposure to either drug significantly increased cell death compared to the current standard of care, gemcitabine. Treatment with combinations of the drugs led to significant increases in cell death compared to either monotherapy. Strong additive/synergistic interactions were observed across a range of dosages and ratios, reducing dose requirements with potential clinical relevance.
The data obtained in this PDAC cell model: i) support the use of matched monotherapies; ii) indicate the effectiveness of matched combination therapies; and iii) provide potential proof-of-concept for precision medicine approach to cancer treatment.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12434</identifier><identifier>PMID: 29599312</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adenocarcinoma ; Apoptosis ; Cancer ; Cell death ; Gemcitabine ; Mutation ; Pancreas ; Pancreatic cancer ; Precision medicine ; Proteins</subject><ispartof>Anticancer research, 2018-04, Vol.38 (4), p.1967-1977</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Apr 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29599312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bush, Kevin T</creatorcontrib><creatorcontrib>Boichard, Amelie</creatorcontrib><creatorcontrib>Tsigelny, Igor F</creatorcontrib><title>In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Advances in therapies targeting proteins and pathways affected by genetic alterations has raised the possibility of personalized cancer treatments.
The efficacy of targeting molecular aberrations was determined in the pancreatic ductal adenocarcinoma (PDAC) cell line, CAPAN2. Two mutations were targeted, KRAS (p.G12V) and ABL1 (p.G1060D), and cells were treated with regorafenib and trametinib, individually and in combination.
Exposure to either drug significantly increased cell death compared to the current standard of care, gemcitabine. Treatment with combinations of the drugs led to significant increases in cell death compared to either monotherapy. Strong additive/synergistic interactions were observed across a range of dosages and ratios, reducing dose requirements with potential clinical relevance.
The data obtained in this PDAC cell model: i) support the use of matched monotherapies; ii) indicate the effectiveness of matched combination therapies; and iii) provide potential proof-of-concept for precision medicine approach to cancer treatment.</description><subject>Adenocarcinoma</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cell death</subject><subject>Gemcitabine</subject><subject>Mutation</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Precision medicine</subject><subject>Proteins</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkMtKxTAQhoMoerw8gBsJuHFTzSRp2izlHG8gKHjZlpxkKpE20aRdnLe3eryAq2GG7_8ZPkIOgZ1yqCtxZsLgrQkJ8ylwKeQGmUGloahKwTbJjPGSFRVj5Q7ZzfmVMaV0LbbJDtel1gL4jJibQJ_9kCK96EbrnRl8DDS2dJHGFzqP_dKH9e1hFTC9rKgP9DGhGXoMwyd4b4L93L2li9EOpqPnDkO0JlkfYm_2yVZruowH33OPPF1ePM6vi9u7q5v5-W1hBZdD4azj3GHFpValFghCqaWqTVtWKKDmBhwDhy22UjtVC95yO2HoFAAoo8UeOVn3vqX4PmIemt5ni11nAsYxN5xxJrWUpZjQ43_oaxxTmL5rOIiaVcC1nChYUzbFnBO2zVvyvUmrBljz5b_58998-Z8yR9_N47JH95v4ES4-AHoJg2g</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Bush, Kevin T</creator><creator>Boichard, Amelie</creator><creator>Tsigelny, Igor F</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180401</creationdate><title>In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma</title><author>Bush, Kevin T ; Boichard, Amelie ; Tsigelny, Igor F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-dcd22de72496593e1366b68af57e3182a1d01defef49d6832f2c93eed61116a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cell death</topic><topic>Gemcitabine</topic><topic>Mutation</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Precision medicine</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bush, Kevin T</creatorcontrib><creatorcontrib>Boichard, Amelie</creatorcontrib><creatorcontrib>Tsigelny, Igor F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bush, Kevin T</au><au>Boichard, Amelie</au><au>Tsigelny, Igor F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>38</volume><issue>4</issue><spage>1967</spage><epage>1977</epage><pages>1967-1977</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Advances in therapies targeting proteins and pathways affected by genetic alterations has raised the possibility of personalized cancer treatments.
The efficacy of targeting molecular aberrations was determined in the pancreatic ductal adenocarcinoma (PDAC) cell line, CAPAN2. Two mutations were targeted, KRAS (p.G12V) and ABL1 (p.G1060D), and cells were treated with regorafenib and trametinib, individually and in combination.
Exposure to either drug significantly increased cell death compared to the current standard of care, gemcitabine. Treatment with combinations of the drugs led to significant increases in cell death compared to either monotherapy. Strong additive/synergistic interactions were observed across a range of dosages and ratios, reducing dose requirements with potential clinical relevance.
The data obtained in this PDAC cell model: i) support the use of matched monotherapies; ii) indicate the effectiveness of matched combination therapies; and iii) provide potential proof-of-concept for precision medicine approach to cancer treatment.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>29599312</pmid><doi>10.21873/anticanres.12434</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2018-04, Vol.38 (4), p.1967-1977 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2020494453 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Adenocarcinoma Apoptosis Cancer Cell death Gemcitabine Mutation Pancreas Pancreatic cancer Precision medicine Proteins |
| title | In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T16%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Elucidation%20of%20Drug%20Combination%20Synergy%20in%20Treatment%20of%20Pancreatic%20Ductal%20Adenocarcinoma&rft.jtitle=Anticancer%20research&rft.au=Bush,%20Kevin%20T&rft.date=2018-04-01&rft.volume=38&rft.issue=4&rft.spage=1967&rft.epage=1977&rft.pages=1967-1977&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12434&rft_dat=%3Cproquest_cross%3E2138071294%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138071294&rft_id=info:pmid/29599312&rfr_iscdi=true |